Thiogenesis Therapeutics CorpOTC Pink - Current Information:TTIPFView on Canadian Exchange
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0016/ 200
- Ask / Lots2.4900/ 1
- Open / Previous Close--- / 0.0000
- Day Range---
- 52 Week Range---
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 4, 2024
Thiogenesis Announces Important Core Patent Allowed in Europe, from 9:02AM ET on Monday Nov 04, 2024 by Dow Jones
9:02AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Thiogenesis Therapeutics Corp | 30.9M | --- | --- |
Company Information
Thiogenesis Therapeutics, Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is developing sulfur-containing prodrugs that act as precursors with the potential to treat serious pediatric diseases with unmet medical needs. The Company’s lead compound, TTI-0102, is a disulfide, made up of two thiols that lead to two independent cysteamine molecules. Cysteamine is a thiol that has been rigorously studied and tested. It is the active ingredient used in drugs to treat the lysosomal storage disease - (nephropathic) cystinosis. TTI-0102 has been developed to address the obstacles facing thiol-based drugs, their short half-life, gastrointestinal (GI) side effects and dosing limitations. As a prodrug, TTI-0102 is metabolized into cysteamine molecules after it is ingested. The metabolic process acts as a gating mechanism. TTI-0102’s initial applications are for MELAS, Leigh syndrome, Rett syndrome and pediatric non-alcoholic steatohepatitis (NASH).
Contact Information
- Headquarters
- 4 King Street West, Suite 401Toronto, ON, Canada M5H 1B6
- Phone
- 647-846-7766
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $30.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 45.5M |
Thiogenesis Therapeutics Corp does not pay a dividend. | |
Beta | --- |
EPS | $-0.10 |
Book Value | $0.12 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
